Fugacar Overdose

Rating: 5 - 1 review(s)
Is this medication very expensive?
sponsored

What happens if I overdose Fugacar?

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Fugacar:

Store Fugacar at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Fugacar out of the reach of children and away from pets.

Overdose of Fugacar in details

When a dose is taken in higher dose than the recommended doses, it is called Overdose. Overdose always needs a clinical supervision. Any medicine or drug when consumed in Overdose produces untoward side effects on one or various organs in the body. A medicine is excreted in the kidney or metabolized in the liver most of the times. This process goes without any hurdles when taken in normal dose, but when taken in an overdose, the body is not able to metabolize it or send it out properly which causes the effects of anoverdose.
sponsored

In patients treated at dosages substantially higher than recommended or for prolonged periods of time, the following adverse reactions have been reported: alopecia, reversible transaminase elevations, hepatitis, agranulocytosis, neutropenia, and glomerulonephritis.

Symptoms and signs

In the event of accidental overdose, gastrointestinal signs/symptoms may occur.

Treatment

There is no specific antidote.

What should I avoid while taking Fugacar?

Treatment of family members and other close contacts may be necessary. Pinworm is spread very easily to others in close contact with the infected person.

To prevent reinfection, toilets must be disinfected daily, and clothing, linens, towels, and pajamas must be changed and washed daily.

Fugacar warnings

Warnings are a mix of Precautions. Contraindications and interactions and serious harmful effects associated with the medicine intake. A diabetic or Hypertensive patient need to be warned about few drug interactions. A known hypersensitivity patient needs to be careful about the reactions or anaphylactic shock. A pregnant woman or a breastfeeding woman should be warned of certain medications. A Hepatitis [liver disease] patient or a cardiac patient should avoid few drugs.

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For Fugacar, the following should be considered:

Pediatric

Fugacar has been tested in a limited number of children 2 years of age or older and, in effective doses, has not been shown to cause different side effects or problems in children than it does in adults.

Geriatric

Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of Fugacar in the elderly with use in other age groups.

Pregnancy Category C

Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Other Medical Problems

The presence of other medical problems may affect the use of Fugacar. Make sure you tell your doctor if you have any other medical problems, especially:

Crohn’s disease or

Liver disease or

Ulcerative colitis—Patients with these diseases may have an increased chance of side effects from Fugacar.

It is important that your doctor check your progress at regular visits, especially in infections in which high doses are needed. This is to make sure that the infection is cleared up completely and to allow your doctor to check for any unwanted effects.

If your symptoms do not improve within a few days, or if they become worse, check with your doctor.

For patients taking Fugacar for pinworms:

In some patients, pinworms may return after treatment with Fugacar. Washing (not shaking) all bedding and nightclothes (pajamas) after treatment may help to prevent this.

Some doctors may also recommend other measures to help keep your infection from returning. If you have any questions about this, check with your doctor.

For patients taking Fugacar for hookworms or whipworms :

In hookworm and whipworm infections anemia may occur. Therefore, your doctor may want you to take iron supplements to help clear up the anemia. If so, it is important to take iron every day while you are being treated for hookworms or whipworms; do not miss any doses. Your doctor may also want you to keep taking iron supplements for up to 6 months after you stop taking Fugacar. If you have any questions about this, check with your doctor.

What should I discuss with my healthcare provider before taking Fugacar?

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For Fugacar, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to Fugacar or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Fugacar has been tested in a limited number of children 2 years of age or older and, in effective doses, has not been shown to cause different side effects or problems in children than it does in adults.

Geriatric

Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of Fugacar in the elderly with use in other age groups.

Pregnancy

Pregnancy Category Explanation
All Trimesters C Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of Fugacar. Make sure you tell your doctor if you have any other medical problems, especially:

Fugacar precautions

Certain people who are very sick or very old or who are sensitive show an exacerbation of side effect of the drug which can turn dangerous at times. So, it is very important to remember the precautions while taking the medicine. Pregnancy and Breastfeeding are also special categories wherein extra care or precaution is needed when taking a drug. Few patients may have a hypersensitivity reaction to few medications, and that can be life-threatening rarely. Penicillin hypersensitivity is one example. Diarrhea, rashes are few other symptoms which need a watch. A patient with other co-existing diseases like liver disease, heart disease, kidney disease should take special precautions.
sponsored

Risk Of Convulsions

Convulsions have been reported in infants below the age of 1 year during post-marketing experience with Fugacar.

Hematologic Effects

Agranulocytosis and neutropenia have been reported with Fugacar use at higher doses and for more prolonged durations than is recommended for the treatment of soil-transmitted helminth infections. Monitor blood counts if Fugacar™ CHEWABLE is used at higher doses or for prolonged duration.

Metronidazole Drug Interaction And Serious Skin Reactions

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have been reported with the concomitant use of Fugacar and metronidazole. Avoid concomitant use of Fugacar and metronidazole.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

In carcinogenicity tests of Fugacar in mice and rats, no carcinogenic effects were seen at doses as high as 40 mg/kg (0.4 to 0.8-fold the MRHD, based on mg/m²) given daily over two years. No mutagenic activity was observed with Fugacar in a bacterial reverse gene mutation test. Fugacar was mutagenic in the absence of S-9 when tested using a continuous (24 hour) treatment incubation period in the mouse lymphoma thymidine kinase assay. Fugacar was aneugenic in vitro in mammalian somatic cells. In the in vivo mouse micronucleus assay, orally administered Fugacar induced an increased frequency of micronucleated polychromatic erythrocytes with evidence suggestive of aneugenicity. Doses up to 40 mg/kg in rats (0.8-fold the MRHD, based on mg/m²), given to males for 60 days and to females for 14 days prior to gestation, had no effect upon fetuses and offspring.

Use In Specific Populations

Pregnancy

Risk Summary

The available published literature on Fugacar use in pregnant women has not reported a clear association between Fugacar and a potential risk of major birth defects or miscarriages. There are risks to the mother and fetus associated with untreated helminthic infection during pregnancy.

In animal reproduction studies, adverse developmental effects (i.e., skeletal malformations, soft tissue malformations, decreased pup weight, embryolethality) were observed when Fugacar was administered to pregnant rats during the period of organogenesis at single oral doses as low as 10 mg/kg (approximately 0.2-fold the maximum recommended human dose (MRHD)). Maternal toxicity was present at the highest of these doses.

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Disease-Associated Maternal And/Or Embryo/Fetal Risks

Untreated soil-transmitted helminth infections in pregnancy are associated with adverse outcomes including maternal iron deficiency anemia, low birth weight, neonatal and maternal death.

Data

Human Data

Several published studies, including prospective pregnancy registries, case-control, retrospective cohort, and randomized controlled studies, have reported no association between Fugacar use and a potential risk of major birth defects or miscarriage. Overall, these studies did not identify a specific pattern or frequency of major birth defects with Fugacar use. However, these studies cannot definitely establish the absence of any Fugacar-associated risk because of methodological limitations, including recall bias, confounding factors and, in some cases, small sample size or exclusion of first trimester Fugacar exposures.

Animal Data

Embryo-fetal developmental toxicity studies in rats revealed no adverse effects on dams or their progeny at doses up to 2.5 mg/kg/day on gestation days 6-15 (the period of organogenesis). Dosing at ≥ 10 mg/kg/day resulted in a lowered body weight gain and a decreased pregnancy rate. Maternal toxicity, including body weight loss in one animal and maternal death in 11 of 20 animals, was seen at 40 mg/kg/day. At 10 mg/kg/day, increased embryo-fetal resorption (100% were resorbed at 40 mg/kg/day), decreased pup weight and increased incidence of malformations (primarily skeletal) were observed. Fugacar was also embryotoxic and teratogenic in pregnant rats at single oral doses during organogenesis as low as 10 mg/kg (approximately 0.2-fold the MRHD, based on mg/m²).

In embryo-fetal developmental toxicity studies in mice dosed on gestation days 6-15, doses of 10 mg/kg/day and higher resulted in decreased body weight gain at 10 and 40 mg/kg/day and a higher mortality rate at 40 mg/kg/day. At doses of 10 mg/kg/day (approximately 0.1-fold the MRHD, based on mg/m²) and higher, embryo-fetal resorption increased (100% at 40 mg/kg) and fetal malformations, including skeletal, cranial, and soft tissue anomalies, were present. Dosing of hamsters and rabbits did not result in embryotoxicity or teratogenicity at doses up to 40 mg/kg/day (0.6 to 1.6-fold the MRHD, based on mg/m²).

In a peri-and post-natal toxicity study in rats, Fugacar did not adversely affect dams or their progeny at 20 mg/kg/day. At 40 mg/kg (0.8-fold the MRHD, based on mg/m²), a reduction of the number of live pups was observed and there was no survival at weaning. No abnormalities were found on gross and radiographic examination of pups at birth.

Lactation

Risk Summary

Limited data from case reports demonstrate that a small amount of Fugacar is present in human milk following oral administration. There are no reports of effects on the breastfed infant, and the limited reports on the effects on milk production are inconsistent. The limited clinical data during lactation precludes a clear determination of the risk of Fugacar™ CHEWABLE to a breastfed infant; therefore, developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Fugacar™ CHEWABLE and any potential adverse effects on the breastfed infant from Fugacar™ CHEWABLE or from the underlying maternal condition.

Pediatric Use

The safety and effectiveness of Fugacar™ CHEWABLE 500 mg tablets have been established in pediatric patients 1 to 16 years of age. Use of Fugacar™ CHEWABLE 500 mg tablets in children is supported by evidence from adequate and well-controlled studies of Fugacar™ CHEWABLE 500 mg tablets.

The safety and effectiveness of Fugacar, including Fugacar™ CHEWABLE have not been established in pediatric patients less than one year of age. Convulsions have been reported with Fugacar use in this age group.

Geriatric Use

Clinical studies of Fugacar did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.

Adult Use

The safety and effectiveness of Fugacar™ CHEWABLE 500 mg tablets have been established in adults for the treatment of gastrointestinal infections by T. trichiura and A. lumbricoides. Use of Fugacar™ CHEWABLE 500 mg tablets in adults for these indications is supported by evidence from an adequate and well-controlled trial in pediatric patients ages 1 to 16 years, safety data in adults, pharmacokinetic data in adults, and the evidence from published literature.

What happens if I miss a dose of Fugacar?

When you miss a dose, you should take it as soon as you remember, but you should take care that it should be well spaced from the next dose. You should not take an extra dose at the time of the second dose as it will become a double dose. The double dose can give unwanted side effects, so be careful. In chronic conditions or when you have a serious health issue, if you miss a dose, you should inform your health care provider and ask his suggestion.

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

Call your doctor if you miss more than one dose of this medicine.


sponsored

References

  1. DailyMed. "MEBENDAZOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DrugBank. "mebendazole". http://www.drugbank.ca/drugs/DB00643 (accessed September 17, 2018).
  3. MeSH. "Tubulin Modulators". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved